{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T15:39:18Z","timestamp":1791128358680,"version":"4.1.0"},"reference-count":31,"publisher":"The Fukushima Society of Medical Science","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fukushima J. Med. Sci.","FJMS"],"published-print":{"date-parts":[[2006]]},"DOI":"10.5387\/fms.52.1","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T23:53:30Z","timestamp":1389225210000},"page":"1-11","source":"Crossref","is-referenced-by-count":20,"title":["ANTI-CALRETICULIN ANTIBODIES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE"],"prefix":"10.5387","volume":"52","author":[{"given":"KENYA","family":"WATANABE","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HIROMASA","family":"OHIRA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HIROSHI","family":"ORIKASA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KEIETSU","family":"SAITO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KAORI","family":"KANNO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YASUO","family":"SHIOYA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KATSUTOSHI","family":"OBARA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YUKIO","family":"SATO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3342","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Rokeach LA, Haselby JA, Meilof JF, Smeenk RJT, Unnasch TR, Greene BM, Hoch SO. Charaterization of the autoantigen calreticulin. J Immunol, <b>147<\/b>: 3031-3039, 1991.","DOI":"10.4049\/jimmunol.147.9.3031"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Michalak M, Milner RE, Burns K, Opas M. Calreticulin. Biochem J, <b>285<\/b>: 681-692, 1992.","DOI":"10.1042\/bj2850681"},{"key":"3","unstructured":"3. Sontheimer RD, Nguyen TQ, Cheng ST, Lieu TS, Capra JD. The unveiling of calreticulin-a clinically relevant tour of modern cell biology. J Invest Med, <b>43<\/b>: 362-370, 1995."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kishore U, Sontheimer RD, Sastry KN, Zappi EG, Hughes GRV, Khamashta MA, Reid KDM, Eggleton P. The systemic lupus erythematosus (SLE) disease autoantigen-calreticulin can inhibit C1q association with immune complex. Clin Exp Immunol, <b>108<\/b>: 181-190, 1997.","DOI":"10.1046\/j.1365-2249.1997.3761273.x"},{"key":"5","unstructured":"5. Routsias JG, Tzioufas AG, Sakarellos-Daitsiotis M, Sakarellos C, Moutsopoulos HM. Calreticulin synthetic peptide analogues: anti-peptide antibodies in autoimmune rheu-matic diseases. Clin Exp Immunol, <b>91<\/b>: 437-441, 1993."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Eggleton P, Llewellyn DH. Pathophysiological roles of calreticulin in autoimmune disease. Scand J Immunol, <b>49<\/b>: 466-473, 1999.","DOI":"10.1046\/j.1365-3083.1999.00542.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Le Naour F, Brichory F, Misek DE, Br&eacute;chot C, Hanash SM, Beretta L. A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analy-sis. Mol Cell Proteomics, <b>1<\/b>: 197-203, 2002.","DOI":"10.1074\/mcp.M100029-MCP200"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Khalife J, Trottein F, Schacht AM, Godin C, Pierce RJ, Capron A. Cloning of the gene encoding a Schistosoma mansoni antigen homologous to human Ro\/SS-A autoantigen. Mol Biochem Parasitol, <b>57<\/b>: 193-202, 1993.","DOI":"10.1016\/0166-6851(93)90195-4"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Boehm J, Orth T, Van Ngyuyen P, S&ouml;ling HD. Systemic lupus erythematosus is associated with increased autoantibody titers against calreticulin and Grp94, but calreticulin is not the Ro\/SS-A antigen. Eur J Clin Invest, <b>24<\/b>: 248-257, 1994.","DOI":"10.1111\/j.1365-2362.1994.tb01082.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Rokeach LA, Zimmerman PA, Unnasch TR. Epitopes of the Onchocerca volvulus RALl antigen, a member of the calreticulin family of proteins, recognized by sera from patients with Onchocersiasis. Infect Immun, <b>62<\/b>: 3696-3704, 1994.","DOI":"10.1128\/IAI.62.9.3696-3704.1994"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kreisel W, Siegel A, Bahler A, Spamer C, Schiltz E, Klein R. High prevalence of antibodies to calreticulin of the IgA class in primary biliary cirrhosis : a possible role of gut-derived bacterial antigens in its aetiology? Scand Univ Press, <b>6<\/b>: 623-628, 1999.","DOI":"10.1080\/003655299750026100"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. S&aacute;nchez D, Tuckova L, Mothes T, Kreisel W, Bene? Z, Tlaskalov&aacute;-Hogenov&aacute; H. Epitopes of calreticulin recognized by IgA autoantibodies from patients with hepatic and celiac disease. J Autoimmun, <b>21<\/b>: 383-392, 2003.","DOI":"10.1016\/S0896-8411(03)00137-9"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Krupickov&aacute; S, Tuckov&aacute; L, Flegelov&aacute; Z, Michalak M, Walter JRF, Whelan A, Harries J, Vencovsky J, Tlaskalov&aacute;-Hogenov&aacute; H. Identification of common epitopes on gliadin, enterocytes, and calreticulin recognized by antigliadin antibodies of patients with coeliac disease. Gut, <b>44<\/b>: 168-173, 1999.","DOI":"10.1136\/gut.44.2.168"},{"key":"14","unstructured":"14. S&aacute;nchez D, Tuckov&aacute; L, &Scaron;ebo P, Michalak M, Whelan A, &Scaron;terzl I, Jel&iacute;nkov&aacute; L, Havrdov&aacute; E, Imramovsk&aacute; M, Bene&scaron; Z, Krupickov&aacute; S, Tlaskalov&aacute;-Hogenov&aacute; H. Occurrence of IgA and IgG autoantibodies to calreticulin in coeliac disease and various autoimmune diseases. J Autoimmun, <b>15<\/b>: 441-449, 2000."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Natter S, Granditsch G, Reichel GL, Baghestanian M, Valent P, Elfman L, Gr&ouml;nlund H, Kraft D, Valenta R. IgA cross-reactivity between a nuclear autoantigen and wheat proteins suggests molecular mimicry as a possible pathomechanism in celiac disease. Eur J Immunol, <b>31<\/b>: 918-928, 2001.","DOI":"10.1002\/1521-4141(200103)31:3<918::AID-IMMU918>3.3.CO;2-L"},{"key":"16","unstructured":"16. Cario E. Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut, <b>54<\/b>: 1182-1193, 2005."},{"key":"17","unstructured":"17. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J, <b>2<\/b>: 1041-1048, 1955."},{"key":"18","unstructured":"18. de Dombal FT, Softley A. IOIBD report no 1 : Observer variation in calculating indices of severity and activity in Crohn's disease. International Organisation for the Study of Inflammatory Bowel Disease. Gut, <b>28<\/b>: 474-481, 1987."},{"key":"19","unstructured":"19. Engvall E, Perlmann P. Enzyme-linked immunosorbent assay (ELISA): quantitative assay of immunoglobulin G. Immunochemistry, <b>8<\/b>: 871-874, 1971."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Chen D, Duggan C, Reden TB, Kooragayala LM, Texada DE, Langford MP. Calreticulin is a binding protein for muramyl dipeptide and peptidoglycan in RK<sub>13<\/sub> cells. Biochem, <b>43<\/b>: 11796-11801, 2004.","DOI":"10.1021\/bi0490789"},{"key":"21","unstructured":"21. Sandborn WJ. Serologic markers in inflammatory bowel disease: state of the art. Rev Gastroenterol Disord, <b>4<\/b>: 167-174, 2004."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Davies DJ, Moran JE, Niall JF, Ryan GB. Segmental necrotizing glomerulonephritis with anti-neutrophil antibody: possible arbovirus aetiology? Br Med J, <b>285<\/b>: 606, 1982.","DOI":"10.1136\/bmj.285.6342.606"},{"key":"23","unstructured":"23. Duerr RH, Targan SR, Landers CJ, Sutherland LR, Shanahan F. Anti-neutrophil cytoplasmic antibodies in ulcerative colitis: comparison with other coli tides\/diarrheal illness. Gastroenterol, <b>100<\/b>: 1590-1596, 1991."},{"key":"24","unstructured":"24. Cambridge G, Rampton DS, Stevens TRJ, McCarthy DA, Kamm M, Leaker B. Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut, <b>33<\/b>: 668-674, 1992."},{"key":"25","unstructured":"25. Sung JY, Chan KL, Hsu R, Liew CT, Lawton WM. Ulcerative colitis and antineutrophil cytoplasmic antibodies in Hong Kong Chinese. Am J Gastroenterol, <b>88<\/b>: 864-869, 1993."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, Seidman EG. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterol, <b>115<\/b>: 822-829, 1998.","DOI":"10.1016\/S0016-5085(98)70252-5"},{"key":"27","unstructured":"27. Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, Charrier G, Targan SR, Colombel JF, Poulain D. Anti-Saccharomyces cerevisiae mannan anti-bodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut, <b>42<\/b>: 788-791, 1998."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Brimnes J, Allez M, Dotan I, Shao L, Nakazawa A, Mayer L. Defects in CD8<sup>+<\/sup> regulatory T cells in the laminapropria of patients with inflammatory bowel disease. J immunol, <b>174<\/b>: 5814-5822, 2005.","DOI":"10.4049\/jimmunol.174.9.5814"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Basu BS, Srivastava PK. Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor-and peptide-specific immunity. J Exp Med, <b>189<\/b>: 797-802, 1999.","DOI":"10.1084\/jem.189.5.797"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Nair SN, Wearsch PA, Mitchell DA, Wassenberg JJ, Gilboa E, Nicchitta CV. Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides. J Immunol, <b>162<\/b>: 6426-6432, 1999.","DOI":"10.4049\/jimmunol.162.11.6426"},{"key":"31","unstructured":"31. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc, <b>71<\/b>: 131-136, 1996."}],"container-title":["FUKUSHIMA JOURNAL OF MEDICAL SCIENCE"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T15:30:29Z","timestamp":1688916629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fms\/52\/1\/52_1\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.5387\/fms.52.1","relation":{},"ISSN":["0016-2590","2185-4610"],"issn-type":[{"value":"0016-2590","type":"print"},{"value":"2185-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006]]}}}